In addition to ibrutinib, patients with M-CLL, devoid of TP53 aberrations and in shape sufficient to tolerate FCR therapy, should be fantastic candidates for the latter, with the gain staying that this remedy can be finished in 6 months when ibrutinib should be taken indefinitely. This selection could be notably useful for non-compliant patients or